News | Magnetic Resonance Imaging (MRI) | January 09, 2018

State-of-the-Art MRI Technology Bypasses Need for Biopsy

New MRI technology out of UT Southwestern Harold C. Simmons Comprehensive Cancer Center eliminates the need for painful biopsy in cancer patients. 

State-of-the-Art MRI Technology Bypasses Need for Biopsy

January 9, 2018 – The most common type of tumor found in the kidney is generally quite small (less than 1.5 in). These tumors are usually found by accident when computerized axial tomography (CAT) scans are performed for other reasons, and the serendipitous finding poses a problem for doctors. Are these tumors malignant and need to be surgically removed because they may threaten the patient’s life? Or are they benign and can be left alone?

The decision is often made with a biopsy. By sampling the tumor, doctors are able to determine whether the cancer is benign or malignant. However, biopsies are invasive procedures and not without risks.

Investigators with the Kidney Cancer Program at UT Southwestern Harold C. Simmons Comprehensive Cancer Center have developed a magnetic resonance imaging (MRI) technology that can provide information about the nature and aggressiveness of the cancer without having to perform a biopsy.

The team, led by Ivan Pedrosa, M.D., and Jeffrey Cadeddu, M.D., co-authors of the study highlighted on the cover of The Journal of Urology, have developed multiparametric magnetic resonance imaging (mpMRI) protocols that tell physicians with high confidence whether the tumor is aggressive or not. These protocols allow investigators to evaluate the chemical composition of the tumor without a biopsy. This composition allows doctors to infer what type of cancer it is.

“Using mpMRI, multiple types of images can be obtained from the renal mass and each one tells us something about the tissue,” said Pedrosa, professor of radiology and chief of magnetic resonance imaging.

The standardized diagnostic algorithm is largely based on the appearance of the renal mass on specific MRI images, namely T2-weighted images and those immediately after intravenous (IV) dye reaches the kidney. Other images are also used that indicate whether fat is present in the tumor. Based on the algorithm, physicians can recognize clear cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer, with 80 pecent confidence.

“Using mpMRI, doctors at UT Southwestern have a four-in-five chance of identifying clear cell cancer” said Pedrosa.

The data collected from this study support the use of mpMRI to reduce the number of biopsies.

“Biopsies are not entirely free of pain and discomfort,” said Cadeddu, professor of urology and radiology at UT Southwestern. “Some patients, in fact, choose to observe the cancer simply to avoid the pain of the biopsy,” he said.

Both Pedrosa and Cadeddu are supported by a Specialized Program of Research Excellence (SPORE) award from the National Cancer Institute.

For more information: www.jurology.com

 

Related Content

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
News | Advanced Visualization | November 13, 2018
Canon Medical Systems USA and Applied Radiology will host a pair of expert-led forums in high-resolution imaging and...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
Fans of Opposing Soccer Teams Perceive Games Differently

Image courtesy of University of York

News | Neuro Imaging | October 25, 2018
Scientists have scanned the brains of die-hard soccer fans to find out why supporters of rival teams often have very...
IMRIS, Siemens Strengthen Collaboration in Hybrid OR Neurosurgical Market
News | Hybrid OR | October 24, 2018
IMRIS, Deerfield Imaging, in partnership with Siemens Healthineers, announced a strengthened collaboration to advance...